title: [Pharmacokinetics of clofibrate in jaundiced newborn infants at term].
abstract: BACKGROUND
  Clofibrate (CFB) has been proposed to increase elimination of bilirubin in neonates with hyperbilirubinemia. Nevertheless, its disposition, at this age, remains unknown. The aim of this work was to characterize pharmacokinetics of an oil formulation of CFB in neonates at term with jaundice.
  
  
  METHODS
  Two groups (G1 and G2) of eight neonates, presenting with jaundice, entered an open, non randomized and comparative study. Five blood samples were collected over 50 hours following a single oral administration of 100 mg/kg or 50 mg/kg CFB, respectively, in G1 and G2. Serum concentrations of both CFB and clofibric acid (CFA) were measured by HPLC and the pharmacokinetic analysis was made by a non-compartmental method. Data were compared to those obtained in adults receiving 2 g dose of CFB.
  
  
  RESULTS
  Tolerance to the treatment was excellent. Pharmacokinetic profiles were similar in both groups of infants. There was a slow and prolonged formation of CFA whose serum concentrations remained high 50 hours after drug administration. Non-hydrolyzed CFB was found in the blood of three neonates. Elimination of CFA was prolonged corresponding to a terminal half-life (t1/2m) often above 100 hours and sometimes incalculable. MRTo-->50 (h) was similar in both groups (ie 26.2 +/- 2.0 vs 25.5 +/- 1.3, respectively). The decrease of t1/2m was related to the decrease of the clearance of CFA.
  
  
  CONCLUSIONS
  The decrease in CFB's metabolism in newborns is probably the result of at least two concurrent phenomenons: partial hydrolysis of CFA, especially at high doses, and decrease in the hepatic capacity to conjugate the active metabolite. A single oral administration of 50 mg/kg CFB seems to be a suitable schedule.
authors.affiliation: Service de pharmacie clinique, groupe hospitalier Necker-Enfants-Malades, Paris, France.
authors.forename: P
authors.initials: P
authors.lastname: Bourget
authors.forename: I
authors.initials: I
authors.lastname: Broise
authors.forename: V
authors.initials: V
authors.lastname: Quinquis-Desmaris
authors.forename: J C
authors.initials: JC
authors.lastname: Gabilan
mesh_terms: D000924:Anticholesteremic Agents / Q000493:pharmacokinetics; D002994:Clofibrate / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D002995:Clofibric Acid / Q000493:pharmacokinetics; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D007567:Jaundice, Neonatal / Q000188:drug therapy / Q000378:metabolism*; D008297:Male
chemical_list: D000924:Anticholesteremic Agents; D002995:Clofibric Acid; D002994:Clofibrate